▁cell ular ▁and ▁perf used ▁organ ▁al log raft s . ▁Initial ly , ▁S la vin ▁pione ered ▁the ▁use ▁of ▁mon oc l onal ▁ant ib od ies ▁anti - CD 5 2 ▁( A lem t uz um ab , ▁now ▁approved ▁by ▁F DA ▁as ▁Lem tr ada ) ▁for ▁prevent ion ▁of ▁gra ft - vs - host ▁disease ▁( GV HD ), ▁the ▁most ▁serious ▁comp lication ▁of ▁al log ene ic ▁stem ▁cell ▁trans plant ation , ▁and ▁later ▁on ▁for ▁treatment ▁of ▁C LL ▁and ▁multiple ▁s cl eros is . ▁Later , ▁S la vin ▁introduced ▁the ▁concept ▁of ▁post - trans plant ▁de ple tion ▁of ▁host - vs - gra ft ▁and ▁gra ft - vs - host ▁re active ▁l ym ph ocy tes ▁with ▁induction ▁of ▁bil ater al ▁trans plant ation ▁toler ance . ▁These ▁discover ies ▁made ▁it ▁possible ▁to ▁extend ▁the ▁use ▁of ▁al log ene ic ▁stem ▁cell ▁trans plant ation ▁using ▁ha p lo ident ical ▁don ors ▁instead ▁of ▁fully ▁matched ▁don ors ▁for ▁sa fer ▁al log ene ic ▁stem ▁cell ▁trans plant ation ▁for ▁every ▁patient ▁in ▁need ▁with ▁h emat ological ▁m align an cies ▁and ▁solid ▁tum ors ▁as ▁well ▁as ▁for ▁induction ▁of ▁trans plant ation ▁toler ance ▁to ▁organ ▁al log raft s . ▁In ▁parallel , ▁S la vin ▁introduced ▁new ▁approaches ▁for ▁treatment ▁of ▁life - th re aten ing ▁auto imm une ▁dise ases ▁based